Lannett Cuts Deal With Celgene In Thalomid Antitrust Case

Law360, San Diego (December 7, 2011, 2:47 PM EST) -- Lannett Co. Inc. on Tuesday resolved its antitrust suit in Pennsylvania federal court alleging Celgene Corp. unfairly blocked it from launching a generic version of Celgene’s thalidomide-based cancer drug Thalomid.

U.S. Magistrate Judge L. Felipe Restrepo dismissed the action with prejudice after the parties notified the court that they had settled their claims against each other.

Samuel Israel, a Fox Rothschild LLP attorney representing Lannett, said his client was pleased with the settlement, but declined further comment because the terms of the deal were confidential....
To view the full article, register now.